Toronto, Ontario – May 27, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF: OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, presented its latest scientific research at the 15th International Photodynamic Association (“IPA”) World Congress in Rio De Janeiro, Brazil from May 22 to 26, 2015.
The latest research details the dramatic increase in targeting and efficacy in the destruction of cancer of Theralase’s lead Photo Dynamic Compound (“PDC”) TLD-1433 when bound to transferrin, in a presentation entitled, “Novel biophysical properties of photosensitizer TLD-1433 upon binding to transferrin”
The IPA was founded in 1986 and its membership consists of the most prominent international clinicians and scientists involved in performing and researching Photo Dynamic Therapy (“PDT”) and Photo Diagnosis (“PD”). The purpose of the IPA is to promote the study of diagnosis and treatment using light and photosensitizers and to disseminate such information to the members of the IPA, the medical community and to the general public. The IPA organises an international congress every two years, which is a unique opportunity to sum up research activities in the clinical and basic research aspects of PDT. The conference encompasses the fundaments of PDT, new photosensitizers and drug delivery, experimental models, PDT for modern dentistry and PD.
About Theralase Technologies Inc.
Theralase Technologies Inc. (“Theralase®”) (TSXV: TLT) (TLTFF: OTC Pink®) in its Therapeutic Laser Technology Division designs, manufactures and markets patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy Division researches and develops specially designed molecules called Photo Dynamic Compounds, which are able to localize to cancer cells and then when laser light activated, effectively destroy them.
Theralase Technologies Inc. was recognized as a TSX Venture 50® company in 2015. TSX Venture 50 is a trademark of TSX Inc. and is used under license.
This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
President & CEO, Theralase Technologies Inc.
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225